Disease-Modifying Therapy

In brief: Disease-modifying therapy is long-term treatment intended to reduce new inflammatory activity and future injury in multiple sclerosis.

Use in multiple sclerosis

DMTs include injectable, oral, infused, and immune-reconstitution approaches. They differ in expected efficacy, infection and immune risks, laboratory and imaging monitoring, reversibility, pregnancy considerations, route, frequency, and access.

Selection is a shared decision based on disease activity, course, prognostic features, prior treatment, comorbidity, vaccination and infection history, reproductive plans, tolerance for risk, and practical burden. The AAN guideline addresses starting, switching, and stopping therapy rather than endorsing one universal sequence. [1]

European guidance similarly links treatment choice and escalation to clinical and MRI activity, efficacy, adverse effects, and safety monitoring. [2]

DMT does not directly treat every symptom and is not the same as corticosteroid treatment for an acute relapse. Rehabilitation and symptom management remain separate parts of care.

Clinical detail

“High efficacy” and “high risk” are not interchangeable labels. Absolute benefit and harm depend on baseline activity, age, prior immune exposure, comorbidities, monitoring, and duration. Stopping some therapies can create rebound risk, so treatment changes require planning.